In subgroup analysis, Patients with KRAS or NRAS mutant tumors should not be treated with cetuximab alone or in combination with other anti-cancer drugs, as they have little chance of benefit and hence the exposure to toxicity and expense are not justified (85). This evidence concerns the gene KRAS and cancer.